Orthotopic liver transplantation in non-alcoholic fatty liver disease patients [0.03%]
非酒精性脂肪性肝病患者的正移植物肝脏移植手术
Patrizia Burra,Giacomo Germani
Patrizia Burra
Non-alcoholic fatty liver disease (NAFLD) is a frequent etiology of liver disease in Western Countries and non-alcoholic steato-hepatitis (NASH) is becoming a leading indication for liver transplantation in US, with constant increase overti...
Use of liver breath tests to assess severity of nonalcoholic fatty liver disease [0.03%]
肝脏呼吸试验在评估非酒精性脂肪肝病严重程度中的应用
Manuele Furnari,Vincenzo Savarino,Edoardo G Giannini
Manuele Furnari
As the prevalence of obesity and insulin-resistance continues to increase in the general population, nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions, thus becoming one of the leading causes of chronic liver disease...
Intestinal permeability in non-alcoholic fatty liver disease: the gut-liver axis [0.03%]
非酒精性脂肪性肝病中的肠黏膜屏障功能及肠道-肝脏轴的作用
E Scarpellini,M Lupo,C Iegri et al.
E Scarpellini et al.
The gut-liver axis model has helped to explain the liver steatosis (NAFLD) and steatohepatitis (NASH) etiopathogenesis. The discovery of a key role for an altered intestinal permeability (IP) in this pathophysioligcal framework has closed t...
Common features of the metabolic syndrome and nonalcoholic fatty liver disease [0.03%]
代谢综合征和非酒精性脂肪肝病的共同特征
Paloma Almeda-Valdes,Nancy Aguilar-Olivos,Misael Uribe et al.
Paloma Almeda-Valdes et al.
Nonalcoholic fatty liver disease (NAFLD) is an important cause of chronic liver disease; including simple steatosis, steatohepatitis, fibrosis, or cirrhosis. The metabolic syndrome (MS) is the existence of metabolic alterations that confer ...
Role of adipokines and cytokines in non-alcoholic fatty liver disease [0.03%]
脂肪细胞因子和细胞因子在非酒精性肝病中的作用
Ludovico Abenavoli,Valentina Peta
Ludovico Abenavoli
One of the most common hepatic manifestations of the metabolic syndrome is non-alcoholic fatty liver disease (NAFLD). This disease varies from simple steatosis to cirrhosis and hepatocellular carcinoma. Different molecules secreted from adi...
Nazarii Kobyliak,Ludovico Abenavoli
Nazarii Kobyliak
Liver biopsy, since 1883, when were first performed, became the gold standard to confirm the earlier stages of fibrosis and grading of non-alcoholic fatty liver disease (NAFLD) and for distinguishing simple steatosis from non- alcoholic ste...
Insulin resistance, non-alcoholic fatty liver disease and hepatitis C virus infection [0.03%]
胰岛素抵抗、非酒精性脂肪肝病和丙型肝炎病毒感染
Nicolas Goossens,Francesco Negro
Nicolas Goossens
Due to their high prevalence, non-alcoholic fatty liver disease (NAFLD), insulin resistance (IR) and hepatitis C virus (HCV) infection are bound to cohabit. However, the relationship between these 3 entities is complex and multilayered. HCV...
Masataka Sawaki
Masataka Sawaki
Targeting anti-HER-2 therapy, trastuzumab, Lapatinib, T-DM1, and Pertuzumab is a standard therapy for HER-2-overexpressing breast cancer. But there are less data available related to anti-HER-2 therapy in elderly patients because they have ...
Antimicrobial sensitivity pattern of bacterial pathogens in urinary tract infections in South Delhi, India [0.03%]
印度德里南部泌尿系感染病原菌的抗菌敏感性模式分析
Mohammad Shabib Akhtar,Nehal Mohsin,Ahmad Zahak et al.
Mohammad Shabib Akhtar et al.
Seventy-four bacterial proven cases of urinary tract infections were studied, and identified by Mac Conkey agar and blood agar medium separately; all the isolates were subjected to antimicrobial sensitivity testing by Stokes technique. Nint...
Fausto Meriggi
Fausto Meriggi
Fatigue is the most common symptom in patients with advanced cancer and its prevalence ranges between 50% to 90% overall. In cancer survivors, approximately 30% of patients will experience persistent fatigue for a number of years after trea...